Literature DB >> 15870438

Cervical cancer in women with comprehensive health care access: attributable factors in the screening process.

Wendy A Leyden1, M Michele Manos, Ann M Geiger, Sheila Weinmann, Judy Mouchawar, Kimberly Bischoff, Marianne Ulcickas Yood, Joyce Gilbert, Stephen H Taplin.   

Abstract

BACKGROUND: Invasive cervical cancer is highly preventable, yet it continues to occur, even among women who have access to cancer screening and treatment services. To reduce cervical cancer among such women, reasons for its occurrence must be better understood. We examined factors associated with the diagnosis of cervical cancer among women enrolled in health plans.
METHODS: We identified all cases of invasive cervical cancer (n = 833) diagnosed from January 1, 1995, through December 31, 2000, among women who were long-term members of seven prepaid comprehensive health plans and reviewed each woman's medical records for the 3 years prior to her cancer diagnosis. Women were classified into one of three categories based on Pap test histories 4-36 months before diagnosis: failure to screen with a Pap test, failure in detection by a Pap test, or failure in follow-up of an abnormal test result.
RESULTS: The majority of cases (n = 464; 56%) were in women who had no Pap tests during the period 4-36 months prior to diagnosis. Of the remaining cases, 263 (32%) were attributed to Pap test detection failure and 106 (13%) to follow-up failure. Being older (odds ratio [OR] = 6.48, 95% confidence interval [CI] = 3.89 to 10.79) or living in an area of higher poverty (OR = 1.72, 95% CI = 1.11 to 2.67) or having a lower education level (OR= 1.52; 95% CI = 1.07 to 2.16) was associated with the likelihood of being assigned to the failure to screen category versus either of the other two categories. A total of 375 (81%) of the 464 patients who had not had Pap screening had had at least one outpatient visit 4-36 months prior to cancer diagnosis. The cancer diagnostic process was triggered by a routine screening examination in 44% of patients, whereas 53% of the patients presented with symptoms consistent with cervical cancer; the remaining 3% were identified fortuitously during the course of receiving noncervical care.
CONCLUSIONS: To reduce the incidence of invasive cervical cancer among women with access to screening and treatment, Pap screening adherence should be increased. In addition, strategies to improve the accuracy of Pap screening could afford earlier detection of cervical cancer.

Entities:  

Mesh:

Year:  2005        PMID: 15870438     DOI: 10.1093/jnci/dji115

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  123 in total

1.  Association Between Risky Sexual Behavior and Cervical Cancer Screening Among Women in Kenya: A Population-Based Study.

Authors:  Zelalem T Haile; Caroline Kingori; Bhakti Chavan; John Francescon; Asli K Teweldeberhan
Journal:  J Community Health       Date:  2018-04

Review 2.  Toward improving the quality of cancer care: addressing the interfaces of primary and oncology-related subspecialty care.

Authors:  Stephen Hunt Taplin; Anne Brown Rodgers
Journal:  J Natl Cancer Inst Monogr       Date:  2010

3.  Determinants of Abnormal Cervical Cancer Screening Follow-Up And Invasive Cervical Cancer Among Uninsured and Underinsured Women in New Jersey.

Authors:  Jennifer Tsui; Adana A Llanos; Michelle Doose; David Rotter; Antoinette Stroup
Journal:  J Health Care Poor Underserved       Date:  2019

4.  Teams and teamwork during a cancer diagnosis: interdependency within and between teams.

Authors:  Stephen H Taplin; Sallie Weaver; Veronica Chollette; Lawrence B Marks; Andrew Jacobs; Gordon Schiff; Carrie T Stricker; Suanna S Bruinooge; Eduardo Salas
Journal:  J Oncol Pract       Date:  2015-04-14       Impact factor: 3.840

5.  Key informants' perspectives prior to beginning a cervical cancer study in Ohio Appalachia.

Authors:  Mira L Katz; Mary Ellen Wewers; Nancy Single; Electra D Paskett
Journal:  Qual Health Res       Date:  2007-01

6.  Human Papillomavirus Vaccine as an Anticancer Vaccine: Collaborative Efforts to Promote Human Papillomavirus Vaccine in the National Comprehensive Cancer Control Program.

Authors:  Julie S Townsend; C Brooke Steele; Nikki Hayes; Achal Bhatt; Angela R Moore
Journal:  J Womens Health (Larchmt)       Date:  2017-03-06       Impact factor: 2.681

7.  Re: Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination.

Authors:  Paolo Giorgi Rossi; Marco Zappa
Journal:  J Natl Cancer Inst       Date:  2008-11-11       Impact factor: 13.506

8.  Acceptability and ease of use of mailed HPV self-collection among infrequently screened women in North Carolina.

Authors:  Chelsea Anderson; Lindsay Breithaupt; Andrea Des Marais; Charlotte Rastas; Alice Richman; Lynn Barclay; Noel T Brewer; Jennifer S Smith
Journal:  Sex Transm Infect       Date:  2017-09-02       Impact factor: 3.519

9.  Achieving Coordinated Care for Patients With Complex Cases of Cancer: A Multiteam System Approach.

Authors:  Simon J Craddock Lee; Mark A Clark; John V Cox; Burton M Needles; Carole Seigel; Bijal A Balasubramanian
Journal:  J Oncol Pract       Date:  2016-10-31       Impact factor: 3.840

10.  Cervical Cancer Screening-Moving From the Value of Evidence to the Evidence of Value.

Authors:  George F Sawaya
Journal:  JAMA Intern Med       Date:  2018-10-01       Impact factor: 21.873

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.